GURGAON, India — Ranbaxy Labs had global sales of $447.6 million in third quarter 2013, compared with $434.6 million in third quarter 2012, the Indian drug maker said Tuesday.
Sales from generics were $208.4 million, while branded and OTC drugs had sales of $239.3 million North American sales were $143.24 million including $128.6 million in the United States, lower than in Q3 2012 due to a large contribution last year from new generic drugs.
"The company continues to grow in its focus branded markets in Asia, East Europe, CIS and Africa," Ranbaxy CEO and managing director Arun Sawhney said. CIS refers to the Commonwealth of Independent States, comprising countries in the former Soviet Union. "In India, however, the announcement of the pricing policy caused some uncertainty in the market, during which our sales in the home market faced some disruptions."